Among about 1,440 users, 56.8% of second-eye events came within six months versus 40.6% for non-users. Researchers stress it shows an association, not cause.
Recap by typeshit. Full story at Newswise.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
@JCanNuSH says Lilly held an investor call for EASD 2026 with no archived audio, and posts a slide with added Phase 3 details on EloraTZP.
Lofton calls the Phase 3 retatrutide results she has seen impressive and notes the drug is drawing a lot of attention right now.
Loading…